Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment.
BACKGROUND
An early virological response (EVR) after the start of interferon (IFN) treatment for chronic hepatitis C leads to a successful virological outcome. To analyze an association between sustained virological response (SVR) and EVR by comparing TaqMan with Amplicor assays in HCV genotype 1-infected patients treated with pegylated (PEG)-IFN alpha-2b plus ribavirin (RBV).


METHODS
We retrospectively analyzed a total of 80 HCV genotype 1 patients (39 SVR and 41 non-SVR patients), who received an enough dosage and a complete 48-week treatment of PEG-IFN alpha-2b plus RBV. Serum HCV RNA levels were measured by both TaqMan and Amplicor assays for each patients at Weeks 2, 4, 8 and 12 after the start of the antiviral treatment.


RESULTS
Of the 80 patients with undetectable HCV RNA by Amplicor, 17 (21.3%) patients were positive for HCV RNA by TaqMan at Weeks 12. The quantification results showed that no significant difference in the decline of HCV RNA level between TaqMan and Amplicor 10-fold method assays within the initial 12 weeks of the treatment was found. However, the qualitative analysis showed significant differences of the positive predictive rates for SVR were found between TaqMan (100% at weeks 4 and 100% at weeks 8) and Amplicor (80.0% and 69.6%, respectively).


CONCLUSIONS
The COBAS TaqMan HCV assay is very useful for monitoring HCV viremia during antiviral treatment to predict a SVR in HCV genotype 1 patients.
Ogawa
Eiichi
E
Department of General Internal Medicine, Kyushu University Hospital, Fukuoka, Japan.
Furusyo
Norihiro
N
Toyoda
Kazuhiro
K
Taniai
Hiroaki
H
Otaguro
Shigeru
S
Kainuma
Mosaburo
M
Murata
Masayuki
M
Sawayama
Yasunori
Y
Hayashi
Jun
J
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics / Q000472:pathogenicity*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000473:pathology / Q000821:virology*; D006801:Humans; D007279:Injections, Subcutaneous; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000627:therapeutic use*; D008099:Liver / Q000473:pathology / Q000821:virology*; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D012367:RNA, Viral / Q000032:analysis*; D011994:Recombinant Proteins; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014774:Virulence
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b
Dig Dis Sci. 1998 Feb;43(2):384-91
9512135
Hepatology. 2001 Aug;34(2):395-403
11481625
J Hepatol. 2003;38 Suppl 1:S104-18
12591189
J Hepatol. 2005 Sep;43(3):425-33
15990196
Hepatology. 2003 Sep;38(3):645-52
12939591
Hepatol Res. 2007 Dec;37(12):1002-10
17608672
J Clin Microbiol. 2000 Jun;38(6):2210-4
10834978
Hepatology. 2004 Apr;39(4):1147-71
15057920
Gut. 2004 May;53(5):744-9
15082595
Arch Intern Med. 1998 Jan 26;158(2):177-81
9448556
J Hepatol. 2002 Oct;37(4):500-6
12217604
Hepatology. 2002 Nov;36(5 Suppl 1):S135-44
12407587
J Med Virol. 2007 Dec;79(12):1821-6
17935166
J Gen Virol. 1993 Nov;74 ( Pt 11):2391-9
8245854
World J Gastroenterol. 2006 Feb 7;12(5):784-90
16521196
N Engl J Med. 1998 Nov 19;339(21):1485-92
9819446
J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 1):1094-104
18248381
Lancet. 1998 Oct 31;352(9138):1426-32
9807989
Dig Dis Sci. 2002 Mar;47(3):535-42
11911338
Gastroenterology. 2006 Apr;130(4):1086-97
16618403
Hepatology. 1997 Mar;25(3):697-701
9049221
J Clin Microbiol. 2000 Nov;38(11):4171-9
11060086
Science. 1998 Oct 2;282(5386):103-7
9756471
J Clin Virol. 2007 Apr;38(4):326-33
17344093